Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

ClinicalTrials.gov ID: NCT01853046

Public ClinicalTrials.gov record NCT01853046. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To characterize the pharmacokinetics and safety of regorafenib in cancer subjects with severe renal impairment when compared to the Control group (cancer subjects with normal or mildly impaired renal function)

Study identification

NCT ID: NCT01853046
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Bayer; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Neoplasms

Interventions

Regorafenib (Stivarga, BAY73-4506) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2013 (Type not available)
Primary completion: Jul 2015 (Actual)
Completion: Nov 2015 (Actual)
Last update posted: Feb 20, 2017

2013 – 2015

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Not listed	Los Angeles	California	90033	—
Not listed	Aurora	Colorado	80045	—
Not listed	St Louis	Missouri	63110	—
Not listed	Lebanon	New Hampshire	03756	—
Not listed	Buffalo	New York	14263-0001	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01853046, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 20, 2017 · Synced Nov 8, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01853046 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →